ERAS shares declined approximately -12% intraday on Monday, April 13, 2026, pulling back sharply from a recent 52-week high of $18.20 reached on April 7. The selloff appears primarily driven by profit-taking and valuation pressure after a staggering ~1,497% rally over the past twelve months, with shares trading well above most pre-run analyst consensus targets.

Replimune Group (REPL) shares collapsed approximately 63.24% in premarket trading on Monday, April 13, 2026, falling from a Friday close of $4.76 to around $1.75. The primary catalyst is the FDA's second consecutive Complete Response Letter (CRL) issued April 10, 2026, rejecting the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma.

Analysts expect Q1 2026 EPS of approximately $4.77-$4.85, up slightly from $4.65 in Q1 2025. Revenue consensus around $22.6B-$23.2B, reflecting 9.7%-4.5% year-over-year growth.

Morgan Stanley (MS) stock surged +15% over the past 30 days, driven by the launch of its low-cost Bitcoin ETF and positive analyst upgrades ahead of Q1 earnings. Over the past quarter, the stock is relatively flat at -1%, reflecting volatility from geopolitical tensions and private credit concerns offset by a strong rebound.

Goldman Sachs ( GS ) reports Q1 2026 earnings on April 13, with consensus EPS of $16.34 and revenue of $16.95 billion, signaling 16% EPS growth year-over-year. Morgan Stanley ( MS ) follows on April 15, expecting EPS of $3.02 and revenue of $19.71 billion, up 16% in EPS.

BAC stock rose approximately +11% over the past 30 days, rebounding from mid-March lows around $47 amid positive net interest income (NII, the difference between interest earned on loans and paid on deposits) guidance and analyst upgrades. Over the past quarter, the stock declined about -5%, reflecting earlier pressures from peak levels near $55 in January due to interest rate volatility and macroeconomic concerns.

ASML stock rose +9.9% over the past 30 days amid AI-driven demand for extreme ultraviolet (EUV) lithography systems, despite volatility from proposed U.S. export restrictions to China. Over the past quarter, shares gained +16.4%, supported by record bookings and strong semiconductor industry capex (capital expenditures) trends.

First Horizon ( FHN ) reports Q1 2026 earnings on April 15, with consensus EPS of $0.49 and revenue of $869 million. F.

INTU stock declined approximately -18% over the past 30 days, driven primarily by sector-wide fears of AI disruption following Anthropic's new model announcements. Over the past quarter, the stock fell around -46%, reflecting broader software sector weakness amid macroeconomic uncertainty and valuation resets.

SMH rose +10.6% over the past 30 days, driven by AI chip demand recovery and easing geopolitical tensions from Iran war ceasefire hopes. Quarterly performance shows +13.0% gain, supported by strong earnings from top holdings like NVIDIA and Taiwan Semiconductor amid sustained AI infrastructure buildout.

Salesforce (CRM) stock declined approximately -12% over the past 30 days amid sector-wide selloffs in software stocks driven by AI disruption fears. Over the past quarter, the stock fell around -35%, reflecting broader YTD losses of over 35% from early-year highs near $260.

Salesforce ( CRM ) boasts a market cap of approximately $155 billion with trailing twelve-month (TTM) revenue of $41.5 billion, dwarfing Atlassian's ( TEAM ) $15 billion market cap and $5.8 billion TTM revenue. Recent market activity has pressured both stocks amid AI disruption fears, but CRM shows resilient AI momentum via Agentforce, with $800 million annual recurring revenue (ARR), up 169% year-over-year.

APP stock declined approximately -20% over the past 30 days amid broader tech sector volatility, ongoing SEC probe concerns, and AI competition fears. Over the past quarter, the stock fell around -44%, reflecting profit-taking after strong Q4 earnings and negative sentiment from short-seller reports.

Both CRWD and MSFT have faced downward pressure in recent market activity, with year-to-date declines around 16-23% amid broader tech sector volatility. CRWD , a cybersecurity specialist, reported strong Q4 FY2026 results with 23% revenue growth to $1.31 billion and ARR of $5.25 billion, but shares dipped on AI disruption concerns.

ORCL stock declined -11% over the past 30 days amid concerns over heavy AI infrastructure spending and analyst price target cuts. Over the past quarter, the stock fell -31%, reflecting broader YTD pressures despite strong Q3 earnings.

MSFT stock declined approximately -8% over the past 30 days, driven by investor concerns over AI infrastructure costs and slowing Azure growth. Over the past quarter, the stock fell around -21%, marking its worst quarterly performance since the 2008 financial crisis amid broader tech sector pressures.

BCS trades at a lower P/E ratio of around 10 compared to JPM 's 15, suggesting relative value in the UK bank amid recent volatility. Both stocks show strong one-year gains, with BCS up over 70% versus JPM 's 38%, but year-to-date JPM edges ahead with positive returns.

C has shown stronger recent momentum, with shares up over 18% in the past month and 7% YTD, outperforming the broader market and JPM 's more modest YTD gains of around 3%. JPM maintains superior scale with a market cap exceeding $830 billion compared to C 's $217 billion, alongside higher profitability metrics like net margins around 30% versus 15%.

BK has outperformed JPM YTD with a 10.3% return compared to 3.4%, and over the past year with 70% versus 38% gains. BK , a custody and asset servicing specialist, shows stronger recent momentum amid rising analyst targets, while JPM benefits from diversified revenue including investment banking.

APLD stock declined -10% over the past 30 days amid volatile trading, closing at $25.57 from $28.52 around March 11, driven by profit-taking and sector pressures despite strong revenue growth. Over the past quarter, the stock fell -20%, from $31.94 around January 10 to $25.57, reflecting broader AI infrastructure stock corrections after earlier peaks near $42.